ambiopharm peptide AmbioPharm - AmbioPharmreviews peptide AmbioPharm: A Global Leader in Peptide Manufacturing and Development

Ambio pharma AmbioPharm has established itself as a prominent global Contract Development and Manufacturing Organization (CDMO) specializing in the intricate field of peptide synthesis and peptide manufacturing. Founded in 2005 and headquartered in North Augusta, South Carolina, USA, AmbioPharm has cultivated extensive expertise in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs).AmbioPharm - 2025 Company Profile

With a robust infrastructure that includes peptide manufacturing and purification facilities in both North Augusta, South Carolina, and Shanghai, China, AmbioPharm is equipped to handle a wide spectrum of projects.2022年10月27日—AmbioPharmis supporting Ariceum with cGMP manufacturing and supply ofpeptideconjugates that will be radio-labelled as the radiopharmaceutical ... The company boasts a large team of over 600 chemists, underscoring its significant capacity and deep talent pool in peptide chemistry. This allows AmbioPharm to serve a diverse clientele, including pharmaceutical and biotech companies, universities, and clinical research laboratories.

AmbioPharm's commitment to quality is evident in its adherence to current Good Manufacturing Practices (cGMP) standards for peptide products. They also provide process development and analytical services for non-cGMP peptides, demonstrating a comprehensive approach to peptide development. The company's capabilities span from producing research-grade peptides in milligram to multi-gram quantities, all fully qualified and released by their in-house Quality Control department, to commercial-scale manufacturing.

The company's specialization in peptide APIs is crucial, given the growing significance of peptides in the pharmaceutical landscape. Currently, there are over 60 peptide-approved drugs on the market, with more than 400 peptide drugs in various stages of clinical development.AmbioPharm, Inc. AmbioPharm plays a vital role in this ecosystem, supporting innovative companies with their peptide manufacturing needs.

AmbioPharm's collaborative efforts highlight their impact. They have partnered with companies like Ariceum Therapeutics, supporting them with cGMP manufacturing and supply of peptide conjugates intended for radiolabeling as radiopharmaceuticals. Similarly, AmbioPharm has been a key partner for ONL Therapeutics, a clinical-stage biopharmaceutical company, in peptide manufacturing and development. This demonstrates AmbioPharm's role in advancing novel peptide-based therapeutics.

The company's business model is designed to handle rapid and complex peptide projects, positioning AmbioPharm as one of the largest capacity peptide API manufacturers globally. Their dedication extends to developing peptide products that can aid in fighting diseases, as exemplified by their expansion of peptide production to help combat COVID-19.AmbioPharmis a full-servicepeptidemanufacturing company. We serve pharmaceutical and biotech companies, universities, and clinical research labs and more ...

For those seeking peptide synthesis services, AmbioPharm offers custom solutions, utilizing multiple manufacturing suites capable of producing research and cGMP peptides and APIs at varying scales. This comprehensive service offering makes AmbioPharm a go-to partner for peptide projects from preclinical stages through to clinical trials and commercialization. The company's forward-looking vision includes becoming a preferred manufacturing partner for a wide range of peptide projects, from small-scale research needs to large-scale commercial production. AmbioPharm's expertise in peptide synthesis and their commitment to quality and innovation solidify their position as a leader in the global peptide industryAmbioPharm - A Global Peptide CDMO Information.